A Study of GC203 TIL in Advanced Malignant Solid Tumors

Sponsor
Shanghai Juncell Therapeutics
Study ID
NCT06375187
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Engineering Tumor Infiltrating Lymphocytes — BIOLOGICAL
    A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.

Study Details

A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors

Key Dates

First listed
Apr 19, 2024
Start date
May 29, 2024
Status verified
Dec 2025
Primary completion
Nov 1, 2026
Completion
May 1, 2027

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL)

Primary Outcome Measure

Maximal Tolerance Dose [ Time Frame: Up to Day 28 ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsLung cancer trialsOncology trialsBreast oncology trialsWomen's health trialsLung oncology trialsLung disease trials

Related Studies